Competitor Analysis: Amyloid beta- and Tau-Targeted Antibodies & Vaccines
Competitor Analysis: Amyloid beta- and Tau-Targeted Antibodies & Vaccines
The Competitive Intelligence Report Amyloid beta- and Tau-Targeted Antibodies & Vaccines as of September 2015 provides a competitor analysis in the development pipeline of novel antibodies and vaccines for passive and active immunotherapy of Alzheimer’s disease or progressive supranuclear palsy (PSP) by targeting amyloid-beta (beta-amyloid) or tau. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of novel antibodies and vaccines for amyloid beta- and tau-targeted passive and active imunotherapy of Alzheimer’s disease. In addition, the report lists company-specific R&D pipelines of amyloid beta- and tau-targeted antibodies & vaccines. Competitor projects are listed in a tabular format providing Information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The Competitive Intelligence Report Amyloid beta- and Tau-Targeted Antibodies & Vaccines as of September 2015 provides a competitor analysis in the development pipeline of novel antibodies and vaccines for passive and active immunotherapy of Alzheimer’s disease or progressive supranuclear palsy (PSP) by targeting amyloid-beta (beta-amyloid) or tau. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of novel antibodies and vaccines for amyloid beta- and tau-targeted passive and active imunotherapy of Alzheimer’s disease. In addition, the report lists company-specific R&D pipelines of amyloid beta- and tau-targeted antibodies & vaccines. Competitor projects are listed in a tabular format providing Information on:
- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product category/Therapeutic Area,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Amyloid beta-Targeted Antibodies
Amyloid beta-Targeted Vaccines
Tau-Targeted Antibodies
Tau-Targeted Vaccines
Corporate Amyloid beta- and Tau-Targeted Antibodies & Vaccines R&D Portfolios
Amyloid beta-Targeted Vaccines
Tau-Targeted Antibodies
Tau-Targeted Vaccines
Corporate Amyloid beta- and Tau-Targeted Antibodies & Vaccines R&D Portfolios
More Publications
Competitor Analysis: Specific and Bispecific Her3 Antibodies
US$ 260.00
February 2015
27 pages
Сompetitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update
US$ 1,450.00
May 2016
462 pages
Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update
US$ 350.00
April 2016
74 pages
Competitor Analysis: Interleukin-17/Receptor (IL-17/R) Antagonists
US$ 170.00
August 2015
20 pages
Competitor Analysis: Rabies Virus Vaccines, Antibodies and Immune Globulins
US$ 255.00
September 2014
33 pages
